Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Adaptimmune Therapeutics PLC changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 80 | 76 | −4 |
| Shares | 162.1M | 153.9M | −8.19M (−5.1%) |
| Value | $256.1M | $150.0M | −$106.1M (−41.4%) |
New holders (7)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 79,239 | $77.0K | 0.01% |
| Jane Street Group, LLC | 75,576 | $73.7K | 0.00% |
| Invesco Ltd. | 34,743 | $33.9K | 0.00% |
| Raymond James & Associates | 10,218 | $9.96K | 0.00% |
| Baader Bank INC | 10,287 | $8.17K | 0.00% |
| IFP Advisors, Inc | 3,023 | $2.95K | 0.00% |
| Parallel Advisors, LLC | 250 | $244 | 0.00% |
Sold out (11)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 675,882 | $1.07M |
| Gsa Capital Partners LLP | 370,179 | $585.0K |
| Harbor Capital Advisors, Inc. | 188,070 | $297.0K |
| Boulder Hill Capital Management LP | 90,800 | $143.5K |
| Jump Financial, LLC | 67,665 | $106.9K |
| Ballentine Partners, LLC | 14,489 | $22.9K |
| Two Sigma Investments, LP | 14,474 | $22.9K |
| Procyon Private Wealth Partners, LLC | 13,000 | $20.5K |
| Atom Investors LP | 10,510 | $16.6K |
| Signaturefd, LLC | 2,037 | $3.22K |
| Royal Bank of Canada | 700 | $1.00K |